Please assess the completion status of the following clinical trial:

Trial Title: Study Of AG-013736 (Axitinib) As Second-Line Treatment In Patients With Metastatic Renal Cell Cancer (mRCC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients histologically diagnosed as metastatic renal cell cancer with a component of clear cell cancer.~* Patients who are refractory to cytokine therapy as 1st line.~* Patients who experienced nephrectomy.~* Patients with at least 1 target lesion, as defined by RECIST.~* Patients with no uncontrolled hypertension.~Exclusion Criteria:~* Gastrointestinal abnormalities~* Current use or anticipated inability to avoid potent CYP3A4 inhibitors or CYP1A2/3A4 inducers.~* Active seizure disorder or evidence of brain metastases.~* Patients with hemoptysis.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AG-013736 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).